ALX Oncology Holdings Inc. (ALXO)
| Market Cap | 222.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -101.70M |
| Shares Out | 134.56M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 767,234 |
| Open | 1.580 |
| Previous Close | 1.590 |
| Day's Range | 1.570 - 1.655 |
| 52-Week Range | 0.404 - 2.660 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 3.50 (+111.48%) |
| Earnings Date | May 8, 2026 |
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 111.48% from the latest price.
News
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapie...
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
ALX Oncology Holdings Transcript: TD Cowen 46th Annual Health Care Conference
Two novel oncology programs are advancing, with evorpacept showing strong efficacy and safety in HER2-positive cancers and ALX2004 progressing in dose escalation. CD47 overexpression is now a key biomarker, and recent financing supports pivotal milestones through 2028.
ALX Oncology Holdings Earnings Call Transcript: Q4 2025
Strong clinical progress in 2025 with Evorpacept and ALX2004, highlighted by robust efficacy in CD47-high cancer patients and a $150M financing extending cash runway through H1 2028. Key data readouts are expected in 2026–2027.
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti...
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...
ALX Oncology Announces Pricing of Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer –
ALX Oncology Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Two differentiated oncology programs advanced, with Evorpacept showing high response rates in HER2-positive cancers and ALX 2004 progressing in phase I. Aspen breast trial targets a large unmet need post-Enhertu, with interim data expected Q3. Both programs aim for registrational studies by year-end.
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim a...
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
- Combination of evorpacept plus rituximab and lenalidomide (R 2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an ap...
ALX Oncology Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference
Evorpacept’s clinical focus has shifted to anti-cancer antibody combinations, showing strong efficacy in HER2-positive cancers, especially with high CD47 expression. The ALX2004 ADC program is advancing in four tumor types, with safety data expected in H1 2026. Cash runway extends into Q1 2027.
ALX Oncology Holdings Transcript: Jefferies London Healthcare Conference 2025
The company is advancing two differentiated programs: evorpacept (CD47) and ALX2004 (EGFR ADC), both showing promising early clinical and safety data. Key milestones in 2025 include phase II breast cancer interim results and phase I ADC safety data, supported by a cash runway into 2027.
ALX Oncology to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...
ALX Oncology Holdings Earnings Call Transcript: Q3 2025
Strong Q3 2025 results highlighted robust efficacy for evorpacept in HER2-positive, CD47 high gastric and breast cancers, and rapid clinical progress for ALX-2004. Cash runway extends into Q1 2027, supporting key milestones in 2026.
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipelin...
ALX Oncology to Participate in Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ther...
ALX Oncology Holdings Earnings Call Transcript: Q2 2025
New ASPEN-06 data validate CD47 as a predictive biomarker for evorpacept, driving a biomarker-focused strategy in HER2-positive cancers. Cash runway now extends to Q1 2027, with key milestones ahead for both evorpacept and ALX-2004.